Description of the medicine: Myelosan (Myelosanum)
Butanediol-1, 4-methylsulfone ester.
Synonyms: Busulfan, Busulfan, Busulphan, Citosulfan, Leukosulfan, Mielucin, Misulban, Mitostan, Myeleukon, Mylecytan, Myleran, Mysulban, Sulfabutin, etc.
White crystalline powder. Very slightly soluble in water and alcohol,
It has a depressing effect on myeloid tissue. Granulocytopoiesis selectively inhibits and gives an antileukemic effect in chronic myelogenous leukemia. The effect of the drug is manifested mainly in a decrease in the number of immature granulocytes.
Used for chronic myeloid leukemia (leukemic form).
Assign inside 2 mg (0.002 g) 1-3 times a day.
With an exacerbation of chronic myelogenous leukemia, accompanied by moderate splenomegaly and an increase in the number of leukocytes up to 200 x 10 9 / l, 4-6 mg per day are prescribed (in 1 to 3 doses). With pronounced splenomegaly and leukocytosis (white blood cells more than 200 x 10 9 / l), the daily dose is increased to 8 - 10 mg (in 2 - 3 doses), and then reduced to 6 - 4 mg when the number of leukocytes becomes less than 200 x 10 9 / l With a decrease in the number of leukocytes to 50 x 10 9 - 40 x 10 9 / l, the daily dose should not exceed 4 mg. The course of treatment ends with hematological remission, which usually occurs no earlier than 3 to 5 weeks after the start of treatment.
Higher doses for adults inside: single 0.006 g (6 mg), daily 0.01 g (10 mg).
With recurrence of myeloid leukemia, repeated courses are carried out, the doses are set depending on the number of leukocytes in the peripheral blood and the course of the disease.
Resistance to myelosan occurs, and the effectiveness of treatment decreases over time. To achieve the desired effect in these cases, an increase in dose is required, which, however, is unsafe. The dose should be increased with great caution, while it is necessary to systematically examine the blood during and after treatment.
With an overdose of myelosan, the inhibitory effect on hematopoiesis can spread to mature granulocytes and platelets with the development of granulocytopenia and thrombocytopenia with hemorrhage. A blood test should be performed at least once every 5 days, and with a decrease in the number of leukocytes to 50 x 10 9 / l -40 x 10 9 / l - every 2 days. During the period of clinical and hematological remissions, a blood test is performed at least 2 times a month.
With severe anemia, a blood or erythrocyte mass transfusion is indicated, with leukopoiesis inhibition, leukopoiesis stimulants, transfusion of stimulating quantities of blood, leukocyte mass; Ascorbic acid, vitamin P, etc. are prescribed.
During treatment with myelosan, vascular dystonia, temporary amenorrhea, skin pigmentation, and oppression of sexual function in men can be observed.
The drug is contraindicated in acute and subacute leukemia, with exacerbation of chronic myelogenous leukemia, if it proceeds as an acute leukemia, with aleukemic and subleukemic forms of chronic leukemia; with severe thrombocytopenia.
Release form: tablets on 0,002 g (2 mg).
Storage: List A. In the dark place.